KAMADA LTD (KMDA) Form 6-K — Sep 17, 2026
Kamada filed a 6-K confirming it maintains sufficient KedRAB supply and manufacturing capacity to meet increased U.S. demand, following a CDC Health Advisory published September 10, 2026 that reported a significant year-over-year rise in nationwide rabies exposures and post-exposure prophylaxis use. KedRAB is one of only two FDA-approved anti-rabies immunoglobulin products in the U.S., a market Kamada estimates at approximately $200 million annually; the CDC estimates roughly 1.4 million Americans seek medical care for possible rabies exposure each year and about 100,000 receive PEP treatment. KedRAB is supplied to the U.S.
Key figures
- Cdc health advisory date
- September 10, 2026
- Us annual pep treatments
- 100000
- Fda approved hrig products in us
- 2
- Us rabies immunoglobulin market usd
- approximately $200 million annually
- Fimi opportunity funds ownership pct
- approximately 38%
- Us annual rabies exposure medical visits
- 1400000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.